Introduction Patient involvement is increasingly recognized as critical to the development, introduction and use (i.e. the lifecycle) of new and effective therapies, particularly those for rare diseases, where natural histories and the impact on patients and families are less well-understood than for common diseases. However, little is known about how patients and families would like to be involved during the lifecycle. Objective The aim of this study was to explore ways in which Canadian patients with rare diseases and their families would like to be involved in the lifecycle of therapies and identify their priorities for involvement. Methods Patients with rare diseases and their families were recruited to participate in two deliberative sessions, during which concepts related to decision-making uncertainty and the technology lifecycle were introduced before eliciting input around ways in which they could be involved. This was followed by a webinar, which was used to further identify opportunities for involvement. The data were then analyzed qualitatively using eclectic coding.
Introduction
It is increasingly recognized that for the benefits of new therapies to be realized by patients with rare diseases, health systems will need to change. Potter et al. state ''There is a need for research to understand and improve health systems for rare diseases in order to ensure that new, efficacious therapies developed through basic and early translational science lead to benefits for patients. Such research must (i) focus on appropriate patient-oriented outcomes; (ii) include robust study designs that can accommodate real-world decision priorities; and (iii) involve effective stakeholder engagement strategies'' [1] . One such stakeholder group comprises patients and families. A recent scoping review identified a variety of opportunities for patients with rare diseases and their families, as well as patient organizations, to be involved in the lifecycle of a therapy [2] , which spans preclinical studies, routine use, and eventual replacement with a new, more effective one. However, these opportunities have often been seen as tokenism (''a false appearance of inclusiveness resulting in a devaluated patients' input'') [3] [4] [5] . In the case of rare diseases, little is known about how patients and their families want to be engaged in the lifecycle of a therapy. Consequently, this study explored how Canadian patients with rare diseases and their families believe they should be involved in the lifecycle of a therapy.
Background
Many patients have knowledge about their disease and its management that may help to inform decisions that need to be made during each stage of the lifecycle of a therapy. Such knowledge can help drive research and development, decisions regarding clinical trial design, valuation of riskbenefit trade-offs during regulatory review, and decisions regarding coverage of the therapy [6] [7] [8] . This is particularly true for rare diseases. A rare disease has been defined as a life-threatening or debilitating, chronic condition affecting less than 1 in 2000 people [9] . Many rare diseases are genetic and develop in childhood. Because they are often poorly understood, patients may spend years without an accurate diagnosis. In addition, for many rare diseases, access to effective therapies is limited, which is in part due to uncertainties in regulatory and coverage decision making (i.e. decisions made by governments on funding new therapies). These uncertainties mainly relate to safety, clinical effectiveness, value for money, and affordability. While decisions on all therapies involve uncertainty, it is magnified for those who treat rare diseases (orphan drugs) [10] . The uncertainty arises from a lack of information traditionally available for common diseases. For many rare diseases, the natural history is poorly understood and clinical trials are small [11] [12] [13] . Published literature suggests that the involvement of patients and families throughout the lifecycle of orphan drugs may help to reduce some of the uncertainties [14] . In this study, three sessions involving patients with rare diseases and their families were held to elicit their views on when and how they would like to be involved during the lifecycle of a therapy.
Methods
Pragmatic qualitative research methods were used in which the methods selected for data collection and analysis were those most likely to provide insights into the research question, without adherence to any specific research approach [15] . Researchers commonly use pragmatic qualitative research to understand the perspectives of a particular group of people [16] .
Patients and families (participants) were recruited through two national events of the Canadian Organization for Rare Disorders (CORD), Canada's national network for organizations representing those with rare disorders. Comprising over 80 disease-specific patient organizations, it provides ''a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders'' [17] . It is a source of information and offers links to other rare disorder organizations across the country. During each CORD event, patients and families were invited to participate in a deliberative session, which was part of the program (see Table 1 for a detailed description). The results of both sessions were discussed at a webinar ( Table 1) . The webinar was an opportunity to ensure that ideas emerging during sessions had been accurately collected by the research team and that any additional insights were captured.
Data Analysis and Interpretation
One researcher (AY) thematically analyzed the audio recordings and field notes from the sessions using eclectic coding [18] . A second researcher (TS) analyzed an overlap of 25% of the recordings and field notes using the same methods to ensure validity of coding. Descriptive and process coding were used to identify the topic (e.g. coverage decision making) and the activity (e.g. providing input), respectively. This yielded a list of activities that patients and families felt they could be involved in. However, additional information on these activities was obtained using values coding (reflecting perspectives, values, attitudes or beliefs about the specific type of engagement), evaluation coding (assigning judgments about the merit, worth, or significance of programs or policy), and emotion coding (labeling the emotions recalled and/or experienced by the patients/families, or inferred by the researcher about the patients/families). Illustrative (Figs. A1, 2, 3 , and 4). The activities were further grouped into goals that patients and families hoped to achieve by participating in those activities they had identified. Interpretation of the results was possibly influenced by the researcher's background. AY has past experience volunteering with youth who have life-threatening and sometimes rare conditions. To minimize bias and ensure the accuracy of the analysis, results were sent to patients and representatives from national rare disease organizations for member checking.
The Comprehensive Criteria for Reporting Qualitative Research (COREQ) checklist was completed and can be found in Online Resource 2 alongside the study flowchart.
Results
Participants identified three overall goals of their involvement: (1) incorporation of the 'lived experience' of patients and families in coverage decision making; (2) improved care for patients; and (3) greater awareness of rare diseases. Tables C1, 2 , and 3 in Online Resource 3 provide a detailed description of the ways in which participants indicated they would like to be involved.
The major themes are briefly summarised below according to the three goals.
Incorporation of the 'Lived Experience' of Patients and Families in Coverage Decision Making
Participants expressed concern over the lack of information considered during coverage decision making that reflects their 'lived experience'. Often, information related to clinical benefit is based on trials that do not capture meaningful outcomes to patients and families. They want to be engaged early in the clinical trial process ''… because we're talking about all the problems that happen after clinical trials are designed by people who know the science and the industry but don't know the disease and that's the problem: we're dealing with the problem because we're not included before the trial begins'' (Patient 1, session 1). In one family member's experience, ''There was no measurement of cognitive function, there was no measurement of all the benefits [they saw] for [the patient]'' (Family member 1, session 1). Participants mentioned two ways in which they would like to be involved: identification and selection of meaningful outcome measures. They also mentioned enrolment in registries and reporting of patient-reported outcome measures (PROMs) during clinical trials as two additional ways of ensuring that trials more holistically captured the effects of a therapy. They felt that while registries can be burdensome and not all patients or families want to participate in them, the benefits outweigh the burden. However, ''Rare disorders need another 10-15 years to come up with the evidence that [decision-makers] say we have to have and that's why [they] deny us. Let's give it to them'' (Patient 1, session 1).
They saw patient organizations as taking a lead in the establishment of disease-based registries, but acknowledged that not all organizations have the required resources. Organizations also need to consider ''ethics, who is owning [the registry], [and] how do you guarantee the privacy …'' (Patient 4, webinar).
Participants also wanted to be more directly involved in coverage decision making by providing feedback on (1) the meaningfulness of outcomes considered by decision makers (''to better qualify what is meant by a benefit''); (2) treatment burden (''they thought it was just a matter of convenience''), including burden on the family; and (3) the benefit-harm ratio and their willingness to accept risk (''what risk you're willing to take on should be taken into consideration''). Furthermore, they wanted the opportunity to identify and provide missing information from a drug submission before a negative decision is made based on insufficient data (''sometimes it could just be that a patient will write it out right, [stating] 'there's something missing''').
Some participants had experience providing input into the Common Drug Review (CDR), the review body that Participants who subsequently participated in the Webinar were given the opportunity to comment on a summary presentation that included their responses from deliberative session 2
provides listing recommendations to all Canadian provinces (except Quebec), through the completion of patient submissions. There was disagreement over the effectiveness of these submissions. Some felt that ''it's very difficult … to explain why you think you need that drug or quality of life on a piece of paper'' (Patient 5, session 1), or patients and patient organizations simply do not know how to use the submission form effectively. Nonetheless, they agreed that patient organizations should still complete patient submissions. Participants also identified their role in managed access programs (MAPs), which are provisional coverage arrangements that aim to provide interim access while information required to support a more definitive coverage decision is generated [19] . Other terms for these programs include managed entry agreements, access with evidence development, and coverage with evidence development [20, 21] . Although none of the participants had previous experience with MAPs, they expressed significant interest in them. They felt their input into the design of such programs would be critical to ensure their meaningfulness to patients and families. The arrangements need to be ''systematic and fair on both sides'' (Family member 4, session 2).
Improved Care for Patients
Participants discussed the highly heterogeneous nature of rare diseases and the importance of considering individual differences when treating a patient with a new orphan drug (''not everybody fits in that square peg hole''-Patient 6, session 1 … ''so [treatment has] got to be flexible, you know, patient-specific''-Patient 8, session 1). They spoke about the fear and confusion that many patients and families have experienced when starting a new treatment. One patient wished they had a patient 'buddy' to talk to as ''one of [the treatments] was really scary and [they were] really frightened'' to begin using it (Patient 2, session 1). In general, participants supported the inclusion of a 'buddy' system through which patients on a drug would provide support for new patients receiving the treatment.
Some felt that stopping criteria for a new drug based on a clinical measure (e.g. percentage increase in lung function) may be inappropriate as patients have very different experiences with drugs that are not captured by clinical outcomes (e.g. being able to walk up a set of stairs). ''Instead of having specific stopping criteria, [the decision around when to stop should be] … stated between the patient and their clinician … [not] a set rule within the drug plan criteria'' (Family member 1, session 1) .
Participants also encouraged engagement with researchers to support development of new projects on potentially beneficial treatments. As one family member shared, ''that's how stem cell transplant therapy started … where the doctors were and the researchers were really encouraged by the parents …'' (Family member 2, session 1).
It was also suggested that patients and patient organizations provide guidance to newly diagnosed patients. Participants described their own struggle to receive a diagnosis and proper care for a disease that is poorly understood. ''This is what a patient organization helps you with'' (Patient 3, session 2) stated one patient, who experienced negative health outcomes due to inappropriate prescribed treatment. Because ''if you don't know the right questions to ask, you won't get information'' (Patient 2, session 2). Patients and patient organizations are able to help other less-experienced patients identify questions to ask their physicians in order to access the treatments and care that they need.
Participants also felt that, as experts on their disease, they should be involved in the development of clinical practice guidelines (CPGs). Some had requests to provide input into the development of a CPG by a pharmaceutical company turned down.
''… maybe once [the pharmaceutical companies] have drafted the guidelines they would be more comfortable'' seeking input from patients (Family member 2, session 2).
Greater Awareness of Rare Diseases
The lack of awareness of rare diseases in Canada and implications for patient care and access to drugs were frequently raised. Participants felt that ''patient organizations can help with that. When we increase our knowledge of where the patients are and let them know that … that's big'' (Family member 2, webinar). ''That is really important, spreading the word. Each individual can bring ten other individuals and, you know, your numbers will multiply when you're doing a petition or letter campaign'' (Patient 4, webinar).
Patient organizations should establish collaborative relationships with all relevant stakeholders (e.g. funders, donors, physicians, etc.) because when ''you build collaboration, you find common goals, and you work on these common goals'' together (Patient 4, webinar).
They should also engage their members by following new research results and sharing them and actively working to convince others to join in the advocacy efforts.
Last, they should promote the global Rare Disease Day on 29 February, and host, help plan, attend, and present at conferences locally and abroad since there are ''… expert patients who can share their knowledge and give their perspective to other patients or even to doctors and health care providers'' (Patient 4, webinar).
Most of the participants had participated in these opportunities and felt that it was important they continue to do so.
Goals and the Orphan Drug Lifecycle
Mapping each identified opportunity onto the orphan drug lifecycle, it became clear that opportunities for involvement spanned the entire lifecycle (see Tables C1, 2 , and 3 in Online Resource 3).
Discussion
This study demonstrated that patients and families want to be and have been involved in the lifecycle of therapies for rare diseases, around which the literature to date is limited. Existing studies have focused on the goals of patient involvement in health technology assessments and coverage decision making as defined by stakeholders other than patients and families [8, 22] . Regarding opportunities for involvement, these findings were consistent with a recent scoping review [2] , as well as a published review on roles for patients and families in research [23] . However, this study identified three additional opportunities: (1) providing input into benefit-harm trade-off assumptions, and willingness to accept risk; (2) identifying missing patientrelated information into coverage decision making; and (3) participating in the design and implementation of MAPs. While discussions around benefit-harm thresholds have typically taken place during regulatory approval (which in some countries involve patients, such as the FDA in the US [24, 25] ), they have increasingly become part of coverage decision making, particularly for orphan drugs. This can be explained by the fact that the small numbers of patients enrolled in these trials often differ from those within a particular jurisdiction. Therefore, assessments of potential clinical benefit during coverage decision making involve significant uncertainty. Patients and families would like the opportunity to reduce that uncertainty by contributing their perspectives.
Along these lines, patients and families could play an important role in participation in MAPs. While different forms of MAPs have been used around the world to provide patients with access to orphan drugs [20] , no evidence of patient and family involvement in their design could be found. It has argued elsewhere that for MAPs to achieve their purpose, all stakeholders must be involved in their development [20] .
Strengths and Weakness of the Study
Both deliberative sessions were conducted at national events hosted by the CORD. Individuals who participated in these events may have differed from those who did not; however, because CORD is comprised of over 80 different rare disease patient organizations and covers travel costs, the likelihood is small.
Conclusion
Opportunities for patients and families to contribute their 'lived experience' are needed throughout the orphan drug lifecycle but the ideal mechanisms for providing this input have yet to be determined.
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